---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216763"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-05-11T20:09:09+00:00"
generated_at: "2026-05-11T22:28:27.298524+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports $140.2M cash; MGX-001 IND on track for Q4 2026

## Summary
- Cash, equivalents and marketable securities of $140.2M at March 31, 2026; runway through Q4 2027.
- MGX-001 for hemophilia A: regulatory submission including IND planned for Q4 2026, first-in-human trials in 2027.
- Kapil Saxena, MD, appointed to lead clinical development for MGX-001; prior roles at Autolus, Bayer, Daiichi Sankyo.
- R&D expenses $19.3M in Q1 2026 (vs $25.1M Q1 2025); G&A $6.5M (vs $6.8M).
- Nature publication on compact CRISPR nuclease MG119-28 with enhanced editing efficiency.

## SEC filing metadata
- accession: 0001193125-26-216763
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-05-11T20:09:09+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/0001193125-26-216763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216763
- JSON: https://secwatch.observer/filing/0001193125-26-216763.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.